Role of antiviral therapy in patients with chronic hepatitis B or C virus in preventing the development of hepatocellular carcinoma

Abstract

Patients with chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection are at significant risk for hepatocellular carcinoma (HCC). The most important risk factor associated with HCC is liver cirrhosis, which is again predominantly caused by chronic HBV or HCV infection. The most effective approach to avoid HCC development is to prevent HBV and HCV infection through vaccination. Indeed, HBV vaccine is the first vaccine demonstrated to prevent cancers. However, a vaccine for HCV is not available. Thus, the prevention of HCV-related HCC and to a large extent HBV-related HCC (among persons who are already chronically infected) will rely on antiviral therapy to prevent progressive liver disease. The evidence that these patients can effectively be protected against HCC risk by the treatment with antiviral therapy is rather controversial, due to the lack of randomized controlled trials (RCTs) that are ideally needed to establish the effi cacy, but are logistically and ethically challenging. Although the strongest evidence to support that antiviral therapy can prevent HCC should be derived from RCTs with HCC as an endpoint, it should be emphasized that clinical trials showing the efficacy of antiviral therapy on virus suppression or eradication, and/or improvement in liver histology can be considered indirect evidence that antiviral therapy can prevent HCC because high virus levels (in the case of HBV infection) and cirrhosis (in both HBV and HCV infection) are the most important risk factors for HCC.

Keywords

Antiviral therapy / cirrhosis / hepatitis B virus / hepatitis C virus / hepatocellular carcinoma / nucleos(t)ide analogs / pegylated interferon / ribavirin

References

[1] Thomas D.New challenges in viral hepatitis..Gut2012;61:i1-5

[2] Mutimer DJ.Management of HBV- and HCV-induced end-stage liver disease..Gut2012;61:i59-67

[3] Colombo M.Role of antiviral treatment for HCC prevention..Best Pract Res Clin Gastroenterol2014;28:771-81

[4] Aghemo A,Colombo M.Assessing long-term treatment efficacy in chronic hepatitis B and C: between evidence and common sense..J Hepatol2012;57:1326-35

[5] Chang MH.Prevention of hepatitis B virus infection and liver cancer..Recent Results Cancer Res2014;193:75-95

[6] Parkin DM.The global health burden of infection-associated cancers in the year 2002..Int J Cancer2006;118:3030-44

[7] Su CH,Cai L.Genetic factors, viral infection, other factors and liver cancer: an update on current progress..Asian Pac J Cancer Prev2013;14:4953-60

[8] Liu CJ,Chen PJ,Huang WL,Chen DS.Role of hepatitis B virus precore/core promoter mutations and serum viral load on noncirrhotic hepatocellular carcinoma: a case-control study..J Infect Dis2006;194:594-9

[9] Orito E.Hepatitis B virus genotypes and hepatocellular carcinoma in Japan..Intervirology2003;46:408-12

[10] Chan HL,Hui AY,Chan FK.Hepatitis B virus genotype C takes a more aggressive disease course than hepatitis B virus genotype B in hepatitis B e antigen-positive patients..J Clin Microbiol2003;41:1277-9 PMCID:PMC150268

[11] Kao JH,Chen DS.Recent advances in the research of hepatitis B virus-related hepatocellular carcinoma: epidemiologic and molecular biological aspects..Adv Cancer Res2010;108:21-72

[12] Zhang KY,Fukai K,Kanda T,Yokosuka O.Analysis of the complete hepatitis B virus genome in patients with genotype C chronic hepatitis and hepatocellular carcinoma..Cancer Sci2007;98:1921-9

[13] Zheng JX,Zheng YY,Zhang DY,Wang F.Role of hepatitis B virus base core and precore/core promoter mutations on hepatocellular carcinoma in untreated older genotype patients..J Viral Hepat2011;18:e423-31

[14] Toh ST,Liu L,Babrzadeh F,Ronaghi M,Chow PK,Ooi LL.Deep sequencing of the hepatitis B virus in hepatocellular carcinoma patients reveals enriched integration events, structural alterations and sequence variations..Carcinogenesis2013;34:787-98

[15] Bonilla Guerrero R.The role of hepatitis B virus integrations in the pathogenesis of human hepatocellular carcinoma..J Hepatol2005;42:760-77

[16] Bouchard MJ.The enigmatic X gene of hepatitis B virus..J Virol2004;78:12725-34 PMCID:PMC524990

[17] Fattovich G,Donato F.Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors..J Hepatol2008;48:335-52

[18] Chen G,Shen F,London WT.Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study..Am J Gastroenterol2006;101:1797-803

[19] Chen CJ,Iloeje UH.Hepatitis B virus DNA levels and outcomes in chronic hepatitis B..Hepatology2009;49:S72-84

[20] Wong GL,Choi PC,Chim AM,Chan HY,Sung JJ.Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B..Gut2009;58:111-7

[21] Chen HP,Chang CC,Lin JT,Lin JH.Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies..Gut2013;62:606-15

[22] Liaw YF,Chow WC,Lee CZ,Tanwandee T,Shue K,Dixon JS,Sabbat J.Lamivudine for patients with chronic hepatitis B and advanced liver disease..N Engl J Med2004;351:1521-31

[23] Wong VW,Mo F,Loong HH,Lui YY,Sung JJ,Chan HL.Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers..J Clin Oncol2010;28:1660-5

[24] Yuen MF,Fong DY,Wong DK,But DY,Wong BC,Lai CL.Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B..J Hepatol2009;50:80-8

[25] Yang HI,Chan HL,Chen PJ,Ahn SH,Wong VW.Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score..Lancet Oncol2011;12:568-74

[26] Papatheodoridis GV,Yurdaydin C,Goulis J,Sypsa V,Mangia G,Keskın O,Hansen BE,Galanis K,Colombo M,Janssen HL.Risk and risk factors of hepatocellular carcinoma in Caucasian chronic hepatitis B (CHB) patients with or without cirrhosis treated with entecavir (ETV) or tenofovir (TDF)..Hepatology2013;58:302A

[27] Papatheodoridis GV,Hadziyannis SJ.The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B..J Hepatol2001;34:306-13

[28] Lin SM,Lee CM,Sheen IS,Liaw YF.Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma..J Hepatol2007;46:45-52

[29] Yuen MF,Cheng CC,Lai YP.Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications..Hepatology2001;34:139-45

[30] Sung JJ,Wong VW,Chan HL.Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma..Aliment Pharmacol Ther2008;28:1067-77

[31] Papatheodoridis GV,Touloumi G,Raptopoulou-Gigi M,Vasiliadis T,Gogos C,Manesis EK.Greece Cohort Study Group. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral (s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece Cohort Study..Gut2011;60:1109-16

[32] Russo FP,Rodrìguez-Castro K,Vanin V.Impact of therapy on long-term outcome of chronic hepatitis B..World J Hepatol2015;18:1097-104 PMCID:PMC4450186

[33] Abu-Amara M.Does antiviral therapy for chronic hepatitis B reduce the risk of hepatocellular carcinoma?.Semin Liver Dis2013;33:157-66

[34] Singal AK,Kuo YF.Meta-analysis: the impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B..Aliment Pharmacol Ther2013;38:98-106

[35] Yang SC,Hu TH,Lu SN,Changchien CS.Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants..J Antimicrob Chemother2013;68:2154-63

[36] Wong GL,Mak CH,Ip ZM,Iu HW,Lai JW,Chan HY.Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis..Hepatology2013;58:1537-47

[37] Kim SS,Park SY,Cheong JY.Virological response to entecavir is associated with low probability of developing hepatocellular carcinoma in chronic hepatitis B patients with cirrhosis..J Hepatol2013;58:S265

[38] Cho JY,Sohn W,Gwak GY,Lee JH,Paik SW.Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease..Gut2014;63:1943-50

[39] European Association for the Study of the Liver.EASL clinical practice guidelines: management of chronic hepatitis B virus infection..J Hepatol2012;57:167-85

[40] Liaw YF,Piratvisuth T,Chien RN,Gane E,Lim SG,Amarapurkar D,Jafri W,Hou JL,Lesmana LA,Suh DJ.Asian-pacfic consensus statement on the management of chronic hepatitis B: a 2012 update..Hepatol Int2012;6:531-61

[41] Lok AS.Chronic hepatitis B: update 2009..Hepatology2009;50:661-2

[42] Hosaka T,Kobayashi M,Kawamura Y,Akuta N,Saitoh S,Ikeda K,Kumada H.Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection..Hepatology2013;58:98-107

[43] Su TH,Liu CJ.Molecular mechanism and treatment of viral hepatitis-related liver fibrosis..Int J Mol Sci2014;15:10578-604 PMCID:PMC4100170

[44] Kumada T,Tada T,Tanikawa M,Kanamori A,Yasuda S,Yamamoto K.Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis..J Hepatol2013;58:427-33

[45] Papatheodoridis GV,Hansen BE,Lampertico P.Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy..J Hepatol2015;62:956-67

[46] Wu CY,Ho HJ,Lee TY,Wu JC.Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study..Gastroenterology2014;147:143-51

[47] Chan AC,Yuen WK,Poon RT,Fan ST.Impact of antiviral therapy on the survival of patients after major hepatectomy for hepatitis B virus-related hepatocellular carcinoma..Arch Surg2011;146:675-81

[48] Huang G,Wang ZG,Yuan SX,Zhou WP.Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma: a randomized controlled trial..Ann Surg2015;261:56-66

[49] Nordenstedt H,El-Serag HB.The changing pattern of epidemiology in hepatocellular carcinoma..Dig Liver Dis2010;42:S206-14

[50] Goodgame B,El-Serag HB.The risk of end stage liver disease and hepatocellular carcinoma among persons infected with hepatitis C virus: publication bias?.Am J Gastroenterol2003;98:2535-42

[51] Hoshida Y,Bardeesy N,Chung RT.Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma..J Hepatol2014;61:S79-90 PMCID:PMC4435677

[52] Bruix J,Practice Guidelines Committee.Management of hepatocellular carcinoma..Hepatology2005;42:1208-36

[53] Chang MH,Chen CJ,Kong MS,Hsu HM,Hsu HY.Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls..JAMA2000;284:3040-2

[54] Manns MP,Gordon SC,Shiffman M,Goodman ZD,Ling M.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial..Lancet2001;358:958-65

[55] Fried MW,Reddy KR,Marinos G,Haussinger D,Carosi G,Craxi A,Hoffman J.Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection..N Engl J Med2002;347:975-82

[56] Hadziyannis SJ,Morgan TR,Diago M,Ramadori G,Bernstein D,Zeuzem S,Lin A.Peginterferon-alpha 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose..Ann Intern Med2004;140:346-55

[57] Nishiguchi S,Nakatani S,Takeda T,Shiomi S,Kobayashi K.Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis..Lancet1995;346:1051-5

[58] Singal AK,Jaganmohan S,Mummadi R,Sood GK.Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis..Clin Gastroenterol Hepatol2010;8:192-9

[59] Yamashita N,Yamasaki A,Kotoh K.Hepatocarcinogenesis in chronic hepatitis C patients achieving a sustained virological response to interferon: significance of lifelong periodic cancer screening for improving outcomes..J Gastroenterol2014;49:1504-13

[60] Moon C,Kim do Y,Park JY,Kim SU,Han KH.Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin..Dig Dis Sci2015;60:573-81

[61] Papatheodoridis GV,Hadziyannis SJ.Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis..Aliment Pharmacol Ther2001;15:689-98

[62] Craxì A.Prevention of hepatocellular carcinoma..Clin Liver Dis2005;9:329-46

[63] Morgan RL,Smith BD,Pitasi M.Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies..Ann Intern Med2013;158:329-37

[64] Morgan TR,Kim HY,Shiffman ML,Lee WM,Bonkovsky HL,Morishima C,Lok AS.Outcome of sustained virological responders with histologically advanced chronic hepatitis C..Hepatology2010;52:833-44 PMCID:PMC2932862

[65] Thévenot T,Ratziu V,Opolon P.Metaanalysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 update..J Viral Hepat2001;8:48-62

[66] Aleman S,Weiland O,Hedenstierna M,Verbaan H,Carlsson T,Ekbom A,Hultcrantz R.A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis..Clin Infect Dis2013;57:230-6

[67] Pinzoni MR,Rapisarda L,Benanti F,Nunnari G.Cirrhotic patients are still at risk of developing hepatocellular carcinoma despite interferon-induced sustained virological response..Eur Rev Med Pharmacol Sci2014;18:11-5

[68] Asahina Y,Tamaki N,Tanaka T,Yasui Y,Ueda K,Nakanishi H,Takahashi Y,Enomoto N.Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection..Hepatology2010;52:518-27

[69] van der Meer AJ,Feld JJ,Dufour JF,Duarte-Rojo A,Manns MP,Zeuzem S,de Knegt RJ,Janssen HL.Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis..JAMA2012;308:2584-93

[70] Arase Y,Suzuki F,Kawamura Y,Kobayashi M,Saito S,Ikeda K,Kobayashi T.Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C..Hepatology2013;57:964-73

[71] Di Bisceglie AM,Everson GT,Everhart JE,Lee WM,Bonkovsky HL,Ghany MG,Snow KK.Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon..N Engl J Med2008;359:2429-41 PMCID:PMC2606037

[72] Afdhal NH,Brown RS,OíBrien M.Colchichine versus peg-interferon alfa-2b long term therapy: results of the 4 year copilot trial..J Hepatol2008;48:S4

[73] Poynard T,Bruix J,Terg R,Moreno-Otero R,Schmidt W,McGarrity T,Gonáales F,Craxi A,Bedossa P,Griffel L,Brass C.Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy..Gastroenterology2009;136:1618-28.e2

[74] Lok AS,Morgan TR,Sterling RK,Everson GT,Lee WM,Dienstag JL,Morishima C.Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease..Gastroenterology2009;136:138-48 PMCID:PMC3749922

[75] Lok AS,Wright EC,Di Bisceglie AM.Maintenance peginterferon (pegIFN) therapy to prevent hepatocellular carcinoma (HCC) in patients (pts) with advanced chronic hepatitis C (CHC): extended follow-up results from the HALT-C Trial..AASLD Abstract;2010;

[76] Hoshida Y,Tanabe KK.Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges..Curr Cancer Drug Targets2012;12:1129-59 PMCID:PMC3776581

[77] Jiang S,Wang L,Liu M.A meta-analysis and systematic review: adjuvant interferon therapy for patients with viral hepatitis related hepatocellular carcinoma..World J Surg Oncol2013;11:240 PMCID:PMC3851844

[78] Singal AK,Anand BS.Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma..Aliment Pharmacol Ther2010;32:851-8

[79] Singal A,Waljee A,Higins P,Marrero JA.Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis..Aliment Pharmacol Ther2009;30:37-47

[80] Lai CL.Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy..Hepatology2013;57:399-408

[81] Shiffman ML.Cure of HCV related liver disease..Liver Int2015;35:71-7